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Abstract
BACKGROUND: Prostate cancer (PCa) is a leading cause of cancer death, and distinguishing aggressive from indo-
lent tumors is a major challenge. Identification and characterization of genomic alterations associated with advanced
disease can provide new markers of progression and better therapeutic approaches. METHODS: We performed
fluorescence in situ hybridization to detect the copy number gain of chromosome 16p13.3 in 75 PCa samples includ-
ing 10 lymph node (LN) metastases and their matched primary tumors, 9 samples of castration-resistant prostate
cancer (CRPC), and 46 additional primary PCa specimens with clinicopathologic parameters. RESULTS:We detected
the gain in 5 of 10 LN metastases and 3 of 5 matched primary tumors, 3 of 9 CRPC samples, and 9 of 46 (20%)
primary tumors where the 16p13.3 alteration was associated with high Gleason score and elevated preoperative
prostate-specific antigen levels. The level of 16p13.3 gain was higher in LN metastasis and CRPC specimens com-
pared to primary PCa. Chromosome mapping revealed the gain spans PDPK1 encoding the 3-phosphoinositide-
dependent protein kinase-1 (PDK1). Knockdown of PDK1 in three PCa cell lines reduced migration without affecting
growth and re-expressing PDK1 rescuedmotility. CONCLUSION:Our findings support a prognostic value of the 16p13.3
gain and a role of PDK1 in PCa progression through migration.
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Introduction
Prostate cancer (PCa) is the most common cancer diagnosed in
North America and, respectively, the third and second leading cause
of cancer death among men in Canada and in USA [1,2]. PCa is
heterogeneous in its clinical outcome ranging from relatively indolent
to aggressive metastatic disease. Key issues in the management of PCa
are to distinguish latent from clinically significant tumors to primar-
ily treat patients with life-threatening disease and to identify mole-
cules contributing to risks of metastatic progression and resistance to
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treatment. The current prognostic tools such as preoperative prostate-
specific antigen (PSA) levels, clinical tumor, node, metastasis (TNM)
staging, and Gleason grading of biopsy specimens cannot accurately
predict individual clinical outcome. Most advanced cancers will re-
spond to androgen deprivation therapy but will invariably relapse
and become castration-resistant prostate cancer (CRPC) [3]. There is
currently no cure for metastatic PCa.
The identification and characterization of genomic alterations asso-
ciated with advanced PCa may lead to developing new progression
markers and more efficient therapeutic approaches. DNA copy num-
ber alterations (CNAs), gains, and losses, have been described in PCa
and include known or candidate tumor suppressors such as NKX3-1
(8p21), PTEN (10q23), RB1 (13q14), and TP53 (17p13), oncogenes
such as MYC (8q24), and the AR (Xq12) in CRPC [4]. Studies using
a genome-wide approach such as array-comparative genomic hybridiza-
tion (CGH) to detect and map CNAs in PCa have confirmed earlier find-
ings implicating losses at 8p and 10q and gains at 8q in disease progression
[5–8]. The 10q23 deletion has been shown to predict PCa recurrence [9]
and earlier prostate cancer–specific death [10]. PTEN is a negative regu-
lator of the phosphatidylinositol 3-kinase/AKT survival pathway known
to be upregulated in several types of cancer [11]. 3-Phosphoinositide-
dependent protein kinase-1 (PDK1) phosphorylates and activates the
AGC kinase members regulated by phosphatidylinositol 3-kinase, in-
cluding AKT that is activated by phosphorylation at Thr308 [12].
Lapointe et al. found that the 16p13.3 gain was among the most
frequent genomic alterations in LN PCa metastases [13], a gain not
yet characterized. In this study, we have mapped the focal 16p13.3
genomic gain and identified PDPK1 encoding PDK1 as the likely
driver of the gain with consequences on PCa cell migration.
Materials and Methods
Ethics Statement
This study was conducted with the written informed consent of
the participants and approval from the Research Ethics Board of
the McGill University Health Centre (study BMD-10-115).
Tissue Samples
Formalin-fixed paraffin-embedded prostate tissue specimens in-
cluded 10 LN metastases and their matched primary tumors, 9 trans-
urethral resections of prostate tissue samples of CRPC (defined by a
rising serum PSA during androgen ablation therapy despite testoster-
one at castrate levels), and 46 primary tumors and adjacent benign
tissues from radical prostatectomy. Gleason score, surgical stage, and
preoperative PSA were available for the latter 46 specimens: 14 cases of
Gleason≤ 6, 25 cases of Gleason = 7, and 7 cases of Gleason≥ 8. The
specimens included 17 tumors of stage ≤ pT2 and 29 tumors of stage
≥ pT3. Duplicate tissue cores (1-mm diameter) were assembled into
tissuemicroarrays (TMAs). Hematoxylin and eosin–stained TMA sections
were reviewed to map representative tumor and benign areas for scoring.
Fluorescence In Situ Hybridization
Dual-color fluorescence in situ hybridization (FISH) was carried out
on TMA sections using the BAC clone RP11-20I23 (BACPAC Re-
sources Center, Oakland, CA) mapping to PDPK1 locus on chromo-
some 16p13.3 region and the recombinant DNA clone pHuR-195
(ATCC, Manassas, VA), which maps to the 16qh centromeric region
[14], as probes. RP11-20I23 and pHuR-195 DNA were, respectively,
labeled with SpectrumOrange-dUTP and SpectrumGreen-dUTP
(Enzo Life Sciences, Farmingdale, NY) using the Nick Translation Re-
agent Kit (Abbott Molecular, Abbott Park, IL). Mapping the regions
flanking 16p13.3 was done using six additional BAC probes: RP11-
243K18, RP11-31I10, RP11-846C9, RP11-698H1, RP11-66H6,
and RP11-548B6. The 5-μm TMA sections were deparaffinized in six
changes of xylene before immersion in 95% ethanol. The slides were
then placed in 0.2 N HCl solution at room temperature for 20 minutes
followed by a 2-hour incubation at 80°C in 10 mM citric acid buffer
(pH 6) for pretreatment. Specimens were digested in 0.1 mg/ml protease
I (Abbott Molecular) and then fixed for 10 minutes in formalin before
dehydration in ethanol series. The two probes and target DNA were co-
denatured at 73°C for 6 minutes and left to hybridize O/N at 37°C
using the ThermoBrite System (Abbott Molecular). Post-hybridization
washes were performed in 2× SSC and 0.3% NP-40/0.4× SSC at 73°C
for 2 minutes and 1 minute, respectively, followed by a 30-second incu-
bation at room temperature in 2× SSC.
FISH Data Analysis
To evaluate the 16p13.3 copy number, we counted fluorescent
signals in 100 nonoverlapping interphase nuclei for each sample (as
identified on corresponding hematoxylin and eosin) counterstained
with 4′,6-diamidino-2-phenylindole (DAPI III; Abbott Molecular) to
delineate nuclei. On the basis of hybridization in 30 benign prostate
cores, the 16p13.3 gain was defined as present at a threshold of
≥15% (mean + 3 standard deviation in controls) of tumor nuclei con-
taining three or more 16p13.3 locus signals and by the presence of
two pHuR-195 signals. Images were acquired with an Olympus IX-81
inverted microscope at ×96 magnification using Image-Pro Plus 7.0
software (Media Cybernetics, Rockville, MD).
Cell Lines
The metastatic human PCa cell lines PC-3, DU145, and LNCaP
(ATCC) were cultured in RPMI 1640 medium with 10% fetal bovine
serum (HyClone, Logan, UT), 1% L-glutamine, and 1% penicillin-
streptomycin (Invitrogen, Grand Island, NY) at 37°C and 5% CO2.
siRNA Transfection
Nontargeting and two specific siRNA (Ctrl, siPDK1-1, and siPDK1-
2) were used in PDK1 silencing experiments. Targeted sequences were
5′-CACGCCUAACAGGACGUAUUA-3′ (siPDK1-1) obtained from
Qiagen (Valencia, CA) and 5′-CAAGAGACCUCGUGGAGAA-3′
(siPDK1-2) as reported in [15], and nontargeting (Ctrl) sequence was
5′-ACGUGACACGUUCGGAGAA-3′ from Qiagen. Twenty-four
hours post-plating, 10 nM siRNA was transfected using HiPerfect
reagent diluted 1:200 according to the manufacturer’s instructions
(Qiagen). Experiments were started 72 hours post-transfection.
Plasmid Construction and Transfection
PDK1 cDNA (GenBank: AF017995.1) was polymerase chain
reaction–amplified from reverse-transcribed RNA extracted from
RWPE-1 prostate cells, sequence-verified, and inserted into the EcoRI
and NotI sites of pcDNA6/V5-HisA (Invitrogen) in-frame with
sequences encoding the V5 epitope. PDK1 reverse transcription–
polymerase chain reaction primers were PDK1-Left with the EcoRI
restriction site: 5′-GATGTGAATTCATGGCCAGGACCACC-
AGCCAG-3′ and PDK1-Right with the NotI restriction site: 5′-CAG-
TATGCGGCCGCTGCACAGCGGCGTCCGG-3′. The pcDNA6–
PDK1-V5 construct was rendered resistant to siRNA by synonymous
nucleotide changes (AACAGGACGTAT to AATCGTACATAC) into
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the targeted sequence of siRNA PDK1-1 by site-directed mutagenesis
(QuikChange Lightning Kit; Stratagene, La Jolla, CA). After deletion
of the DNA region to be mutated, the changed sequences were reinserted
in two steps using the following primers: 5′-CTTTGTCCACACGCC-
TAATATCTGATGGACCCCAG-3′ and 5′-CTGGGGTCCATCAG-




reinsertion of first part), and 5′-AAACTTTCTTTGTCCACACGC-
CTAACATACTATCTGATGGACCCCAGCGGGAAC-3′ and
5′-GTTCCCGCTGGGGTCCATCAGATAGTATGTTAGGCGT-
GTGGACAAAGAAAGTTT-3′ (for reinsertion of second part). After
rendering the pcDNA6–PDK1-V5 construct resistant to siPDK1-1,
siRNA-treated cells were co-transfected with pcDNA6–PDK1-V5
or empty vector (2 or 1.25 μg per well in 6-well and 24-well plates,
respectively) using HiPerfect as described above.
Protein Extraction and Western Blot Analysis
Whole–PCa cell protein extracts were prepared using RIPA buffer
[50 mM Hepes (pH 7.2), 150 mM NaCl, 2 mM EDTA (pH 8.0),
1% NP-40, 0.5% deoxycholate, 1 mM Na3VO4, 10 mM Na4P2O7,
100 mM NaF, and Complete Protease Inhibitor Cocktail by Roche
(Madison, WI)]. Briefly, cell culture medium was removed and cells
were washed thrice with ice-cold phosphate-buffered saline before add-
ing RIPA buffer and scraping the cells off. Cell lysate was then collected
and left to shake on ice for an hour. After overnight freezing, lysates
were centrifuged at 17,000g for 10 minutes and supernatants were
transferred to new tubes. Protein concentration was determined using
Bio-Rad RC DC Protein Assay. Twenty-five micrograms of protein
were loaded on sodium dodecyl sulfate–polyacrylamide gel electropho-
resis, transferred to nitrocellulose membrane, and probed with primary
antibodies: mouse anti-PDK1 at 1:5000 (ECM Biosciences, Versailles,
KY; Cat. No. PM1461), mouse anti-actin at 1:100,000 CHEMICON,
Temecula, CA; Cat. No. MAB1501R0), rabbit anti-AKT at 1:10,000
(Cell Signaling Technology, Danvers, MA; Cat. No. 9272), rabbit
anti–phospho(p)-AKT (Thr308) at 1:1000 (Cell Signaling Technology;
Cat. No. 4056), mouse anti-V5 at 1:5000 (Invitrogen; Cat. No. R960-
25), rabbit anti-PTEN at 1:2000 (Cell Signaling Technology; Cat.
No. 9559), mouse anti-AR at 1:1000 (NeoMarker, Fremont, CA;
Cat No. AR441), and rabbit anti-PSA at 1:2000 (DakoCytomation,
Carpinteria, CA; Cat. No. A0562). Antibodies were diluted in 5%
nonfat dry milk or 5% BSA (for anti–p-AKT) in a solution of TBS/
0.1% Tween-20. Secondary anti-mouse or anti-rabbit HRP-conjugated
antibody (Jackson ImmunoResearch, West Grove, PA; Cat. Nos 715-
035-150 and 711-035-152, respectively) was used at 1:20,000, and
results were revealed using the SuperSignal West Femto Maximum
Sensitivity Substrate (Thermo Scientific, Waltham, MA).
Growth Assay
Survival/proliferation was measured using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in 24-well plates
in triplicates. Cells were plated at 2.5 × 104 cells per well for PC-3,
2.2 × 104 for DU145, and 5.5 × 104 for LNCaP cells. MTT (5 mg/ml)
in phosphate-buffered saline was added to each well at a final concentra-
tion of 0.5 mg/ml, and plates were incubated at 37°C for 4 hours in a
5% CO2 environment. The medium was then carefully removed, and
DMSO was added to cells and left to incubate for 10 minutes at 37°C
and 5% CO2. Readings were done at wavelengths of 595 nm for MTT
reagent and 690 nm for the background (Victor3V 1420 Multilabel
Counter Plate Reader; PerkinElmer, Waltham, MA)
Migration Assay (Wound Healing Assay)
Cells were plated in six-well plates at 1.2 × 105 cells per well for PC-3
and DU145 and at 3 × 105 for LNCaP cells. Seventy-two hours after
transfection, a linear scratch was performed using a pipette tip. Motility
was assessed in duplicates at 3, 6, and 12 hours by computing the
percentage of wound closure relative to initial surface area (0 hour).
At each time point, images were captured with Image-Pro Plus 7.0
software on an Olympus IX-81 inverted microscope at ×10 magni-
fication. For each experiment, MTT assay was done in parallel as
described above.
Figure 1. Dual-color FISH analysis of 16p13.3 gain in formalin-fixed
paraffin-embedded PCa samples. (A) Results of interphase FISH for
chromosome 16p13.3 on 10 LNmetastases (A–J) and their matched
primary tumors. (B) On the left panel, representative FISH images of
LN metastases without gain and their matched primaries show two
red signals (16p13.3 locus) and two green signals (centromere 16)
in most of the nuclei. On the right panel, FISH images show greater
than or equal to three red signals (16p13.3 locus) and two green
signals per nucleus, indicating a 16p13.3 gain. (C) Representative
images of the 16p13.3 gain in a CRPC sample (left panel) and in a
sample from the 46 unmatched primary tumors (right panel).
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Statistical Analysis
Growth and migration assays were done in triplicate and dupli-
cate, respectively, and each experiment was replicated at least twice.
Significance of PDK1 knockdown response on growth and motility
was determined using two-sample t test and P < .05 was considered
to be significant. Clinicopathologic tumor characteristics and their
association with the 16p13.3 gain were assessed using Fisher exact
test. Levels of gain were compared between specimen categories with
the U test (Mann-Whitney).
Results
FISH Analysis of the 16p13.3 Genomic Gain in
PCa Tissue Samples
We used FISH to assess CNAs at the 16p13.3 region on 10 PCa
samples of LN metastases and their matched primary tumors and
9 CRPC samples from transurethral resections of prostate. We found
that 5 of 10 LN metastasis samples harbored the 16p13.3 copy num-
ber gain and 3 of these 5 LN cases showed the gain in their matched
primary samples (Figure 1, A and B). One of the five LN metastases
with no 16p13.3 gain showed the gain in its respective primary
specimen (case F), while four cases did not harbor the gain in their
primary or metastatic samples. The gain was also detected in three of
nine CRPC samples (Figure 1C , left panel).
We surveyed an additional set of 46 primary tumors from radical
prostatectomy for which the clinicopathologic parameters were avail-
able. Found in 9 of these 46 radical prostatectomy specimens (Fig-
ure 1C , right panel), the 16p13.3 gain was significantly associated
with Gleason score≥ 8 (P = .002, Table 1) and preoperative PSA levels
(P = .047) but not with surgical stage (P = .258).
We compared the level of gain in primary radical prostatectomy
samples with CRPC and metastatic samples and more specifically eval-
uated the average percentage of nuclei with more than three copies
of 16p13.3 across the specimens with gain. CRPC (n = 9) and LN
metastasis samples (n = 10) harbored higher percentages of nuclei with
more than three copies than the primary (n = 56, P < .05, Table 1).
Mapping of Chromosome 16p13.3 Gain
To define the extent of 16p13.3 gain, we mapped the flanking
genomic region with FISH using six different BAC probes on the 9
of 46 primary PCa samples with gain for which additional TMA sec-
tions were available for multiple-probe hybridization. The size of the
gain varied from 0.57 to 9 MB (Figure 2A). The minimal region of
gain common to the nine samples was 0.57 MB in size and included
20 genes according to the UCSC Genome Browser, February 2009
assembly. To prioritize candidates at this locus and in absence of gene
expression data for the nine samples mapped here, we looked at the
previous PCa array-CGH study by Lapointe et al. that reported the
16p13.3 gain in five PCa samples (LN metastases) [13] and the cor-
responding gene expression data [16]. Both CNA and gene expression
data were retrieved for 11 of 20 genes residing in the minimal region of
gain. PDPK1 gene had the highest DNA/RNA correlation coefficient
and the only one above 0.5 (Figure 2A). Transcript levels of PDK1,
reported in the same gene expression study, were significantly higher
in tumors with 16p13.3 gain than in samples without 16p13.3 gain
(P < .001, two-tailed Mann-Whitney U test; Figure 2B).
In Vitro Down-regulation of PDK1 Expression and
PCa Cell Migration
PDK1 is expressed in PCa cell lines with different PTEN and
AR status: LNCaP, PC-3, and DU145 (Figure 3). The AR negative
(AR−)/PTEN− PC-3 and the AR+/PTEN− LNCaP express high lev-
els of PDK1, while the AR−/PTEN+ DU145 cells express the lowest.
To explore the role of PDK1 in PCa progression, we downregulated
its expression in these three cell lines with siRNA and assessed the
resulting consequences on growth and migration. siPDK1-1 and
Table 1. 16p13.3 Gain, Clinicopathologic Parameters, and Levels of Gain.
Clinicopathologic Parameters (n = 46) Number of Cases 16p13.3 Status
No Gain Gain
Mean Percentage of Nuclei with
Three Copies
Mean Percentage of Nuclei with
More than Three Copies
Gleason score
≤6 14 (30%) 13 (93%) 1 (7%)
=7 25 (55%) 22 (88%) 3 (12%)
≥8 7 (15%) 2 (29%) 5 (71%)
P = .002*
Surgical stage
≤T2 29 (63%) 25 (86%) 4 (14%)
≥T3 17 (37%) 12 (71%) 5 (29%)
P = .238*
Preoperative PSA (ng/ml)
<10 30 (64%) 27 (90%) 3 (10%)
≥10 16 (36%) 10 (62.5%) 6 (37.5%)
P = .047*
Tumor type
Primary PCa 46 37 (80%) 9 (20%) 20.0 3.4
10 (matched) 6 (60%) 4 (40%) 19.0 13.75
LN metastases 10 5 (50%) 5 (50%) 21.2 19.4; P < .05†,‡
CRPC 9 6 (67%) 3 (33%) 20.7 15.0; P < .05†,§
*Fisher exact test.
†Mann-Whitney U test.
‡LN metastases (n = 10) versus primary PCa (n = 56).
§CRPC (n = 9) versus primary PCa (n = 56).
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siPDK1-2 were used in PC-3, and siPDK1-1 was used in DU145 and
LNCaP cells. Cell migration was significantly reduced when PDK1 was
siRNA downregulated across the three cell lines and the difference with
siCtrl was noticeable at 3 hours into the assay (P < .01, Figure 4).Western
blots were performed in parallel to assess the effect of siRNA on PDK1
protein expression and downstream cell signaling. In all three cell lines,
siRNA effectively downregulated PDK1 expression (assessed by band
quantification relative to actin levels; Figure 5A). In DU145 cells,
down-regulation of PDK1 was the most effective (84% knockdown)
and resulted in a down-regulation of AKT phosphorylation at Thr308
residue, while the knockdown in LNCaP and PC-3 cells did not sub-
stantially affect this phosphorylation site. In all three cell lines, knocking
down PDK1 did not reduce cell growth as measured by MTT assay
(Figure 5B).
To further validate our findings, we re-expressed PDK1 using the
human V5-tagged cDNA resistant to siPDK1-1. Transfection with
a control vector (Mock) did not affect the ability of siPDK1-1 to re-
duce PC-3 cell motility, while re-expressing PDK1 was effective in
rescuing motility and restoring levels to the control value (Figure 6).
Overexpressing PDK1 in siCtrl-transfected cells did not affect motil-
ity. The effects of PDK1 down-regulation and PDK1 re-expression
on motility were noticeable at 3 hours (P < .006) and were even more
significant at 6 and 12 hours (P < .001). Figure 6 shows the effec-
tive down-regulation of PDK1 expression by siRNA and its sub-
sequent re-expression. Levels of p-AKT did not significantly vary across
experimental conditions.
Discussion
The frequency of 16p13.3 gain in our set of PCa LN metastases (50%)
is in line with the previous array-CGH study [13]. Although the num-
ber of metastases available was limited, the detection of this gain in
most matched primary tumors (60%) is in agreement with earlier data
[17] and more recent studies [5,18] showing that metastatic genomic
profiling reflects the original primary tumor. In most LN metastases
with 16p13.3 gain analyzed here, we observed a deletion of 10q23
(PTEN) ([9] and unpublished observations) as found in the previous
array-CGH study [13], which may indicate cooperation between
PDK1 and PTEN in the metastatic process. For cases with no altera-
tions at 10q23 and 16p13.3, alternative genetic pathways may have led
to their metastatic behavior.
The detection of the 16p13.3 gain in prostatectomy specimens
and its association with high Gleason score and high preoperative
PSA levels support the idea of an early marker for aggressive PCa.
The higher levels of 16p13.3 gain found in LN metastases and CRPC
than in radical prostatectomy samples also suggest a link between this
genomic alteration and PCa progression. Recently, a report has shown
that the 16p13.3 gain was associated with poor survival of breast can-
cer patients [19]. A cytogenetic study on lung tumors has found the
16p13.3 gain to be associated with poor differentiation and late stage
disease [20]. Despite the importance of testing its prognostic value on
a larger population of PCa patients with survival data, these findings
Figure 2. Mapping of flanking regions of the 16p13.3 gain and
PDK1 transcript levels in PCa samples. (A) Each BAC probe was co-
hybridized with the centromere 16 probe to nine primary formalin-
fixed paraffin-embedded PCa samples with 16p13.3 gain detected
by FISH. Gains are indicated by red boxes for each sample. The
horizontal dotted lines delineate the minimal region of gain with, on
the far right, the list of genes mapping to this region (UCSC Genome
Browser, February 2009 assembly) with their corresponding DNA/
RNA correlation coefficient calculated from independent and previ-
ously published array-CGH and gene expression data sets [13,16].
(B) PDK1 transcript levels measured in previously published micro-
array data [16] are increased in tumor samples with 16p13.3 gain
compared with samples without 16p13.3 gain [13]. Box plots show
25th, 50th (median), and 75th percentiles as well as maximum and
minimum of sample set expression with P value (two-sided Mann-
Whitney U test). Values are reported as log2 ratios, normalized to
the sample set mean.
Figure 3. PDK1 expression in LNCaP, PC-3, and DU145 PCa cell
lines. Cells were grown in RPMI 1640 medium supplemented with
10%FBS and assessed for basal levels of expression of PDK1, PTEN,
AR, and the androgen-regulated PSA by Western blot analysis. Actin
was used as control.
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suggest a strong clinical relevance for 16p13.3 gain in several can-
cers. Whether this genomic alteration is involved in the development
of CRPC is unknown. The AKT pathway was shown to be activated
in CRPC along with PTEN deletion [21]. Whether the AKT path-
way is further activated in tumors with 16p13.3 gain needs to be as-
sessed, as the observations in LN metastasis suggest that harboring
the PTEN deletion along with the 16p13.3 gain may lead to a worse
clinical outcome.
Although we cannot exclude a role for the other genes in the
16p13.3 region, mapping results and PDK1 mRNA levels correlating
with CNAs in the microarray data sets suggested PDPK1 as a candi-
date driver of the gain. Our study is limited by the lack of data on
PDK1 protein levels in the samples analyzed by FISH. Nevertheless,
the microarray data concord with a recent report on PDK1 overexpres-
sion in breast cancers with increased PDPK1 CNA [19].
In all three PCa cell lines used here, knocking down PDK1 did not
affect cell growth, a finding consistent with in vitro results in mouse
embryonic fibroblast derived from PDK1 knockout mice [22]. The
knockdown of PDK1 reduced however the cell migration that was
rescued by re-expressing PDK1. Recent reports suggested that PDK1
regulates endothelial [23] as well as breast cancer cell migration [19,24]
through phosphorylation of AKT at Thr308. The kinase and PH
domains of PDK1 were necessary for this effect in endothelial cells
[23], and PKCζ was involved in one of the breast cancer studies
[24]. In our study, phosphorylation of AKT at Thr308 was affected
by the reduction of PDK1 levels in DU145 but not in PC-3 and
LNCaP cell lines, while motility was consistently diminished in all
cell lines. Although reduced by siRNA, it is possible that the levels of
PDK1 remained sufficient to maintain the AKT phosphorylation in
PC-3 and LNCaP cells, considering that their basal level of PDK1 is
higher than that of DU145 cells (Figure 3). PC-3 and LNCaP do
not express a functional PTEN, which may further contribute to
the deregulation of AKT phosphorylation. Similar observations were
previously reported in animals showing that AKT phosphorylation re-
mained normal in PDK1 hypomorphic mice expressing reduced levels
of PDK1 [22]. Knockout of PDPK1 by homologous recombination in
Figure 4. PDK1 knockdown reduces PCa cell motility. (A) Wound healing assays for PC-3, DU145, and LNCaP cell lines at 0 and 12 hours
with control siRNA (siCtrl) compared to siPDK1 (siPDK1-1 and siPDK1-2 for PC-3 and siPDK1-1 for DU145 and LNCaP). Dotted lines show
areas used for quantification. Migration results are represented in B (from top to bottom: PC-3, DU145, and LNCaP) in terms of per-
centage recovery of initial surface area after wounding (hour).
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Figure 6. Ectopic expression of siRNA-resistant PDK1 rescues motility in siPDK1-treated PCa cells. The left panel shows the quantified
results of migration comparing PC-3 cells transfected with siCtrl or siPDK1-1 in combination with an empty vector (Mock) or a siRNA-
resistant PDK1-V5 expressing vector at 3, 6, and 12 hours after wounding. AccompanyingWestern blots are shown on the right, representing
expression levels of PDK1, AKT, and p-AKT.
Figure 5. PDK1 knockdown and PC cell growth. (A) Accompanying Western blots of the experiments shown in Figure 4. Residual
expression (percentage relative to siCtrl and normalized to actin) is indicated for PDK1 and p-AKT (relative to siCtrl and normalized to
AKT). (B) The effect of PDK1 knockdown on growth in PCa cell lines. MTT assays were performed on PC-3, DU145, and LNCaP cells, on
the day of transfection (0 hour) and 72 hours post-transfection at time intervals indicated. Cells were transfected with control (siCtrl), siPDK1-1,
or siPDK1-2. Differences between control and PDK1-targeting siRNA were not significant with P ≥ .83.
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human colon cancer cell lines reduced the level but did not abolish
the phosphorylation of AKT at Thr308 [25]. This result suggested that
another kinase can phosphorylate AKT at Thr308, a hypothesis that is
supported by our findings.
Absence of expected effects on the AKT pathway suggests that
PDK1 may modulate PCa cell motility by another mechanism.
PDK1 has been reported to bind ROCK1, a mediator of cell motility,
at the plasma membrane without use of its kinase domain [15]. Loss
of PDK1 diminishes ROCK1 activity and consequently reduces motil-
ity. Further experiments are needed to determine whether such a
mechanism underlies the effect of PDK1 on PCa cell motility.
Given the involvement of PDK1 in motility, it is possible that the
16p13.3 gain detected in primary and LN metastases contributes to
cancer cell migration outside the prostate and one can expect to find
it in circulating tumor cells [26]. In recent CNA surveys of PCa, this
gain was also detected in distant metastasis sites such as the bone,
liver, and adrenal glands [5,18] and was associated with PCa liver
metastases [5]. The latter observation suggests a role for the 16p13.3
gain in PCa cell migration to distant organs, which ultimately leads to
lethal PCa.
Taken together, our results support that the 16p13.3 gain is relevant
to PCa progression and may represent an early marker of metastasis,
since retrieved in primary PCa, which is sampled by biopsies at time
of diagnosis. PDK1, encoded by PDPK1 at 16p13.3, is implicated in
PCa cell motility, a critical step for progression to metastasis. These
findings provide further rationale for considering PDK1 as a target
for cancer therapies and the development of new specific inhibitors
of PDK1 [27].
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